| Schedule of Significant Segment Expenses Regularly Provided to the CODM |
The following table presents certain significant segment expenses that are regularly provided to the CODM (in thousands):
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, |
|
|
2026 |
|
|
2025 |
|
Research and development expenses: |
|
|
|
|
|
GlyphAllo direct research and development expenses |
$ |
8,297 |
|
|
$ |
3,309 |
|
GlyphAgo direct research and development expenses |
|
6,494 |
|
|
|
1,960 |
|
Glyph2BLSD direct research and development expenses |
|
582 |
|
|
|
896 |
|
Preclinical and early discovery assets |
|
944 |
|
|
|
821 |
|
Personnel-related (including stock-based compensation expense of
$0.9 million and $0.5 million for three months ended March 31, 2026
and 2025, respectively) |
|
4,600 |
|
|
|
3,156 |
|
Other indirect research and development expenses |
|
514 |
|
|
|
392 |
|
Total research and development expenses |
|
21,431 |
|
|
|
10,534 |
|
General and administrative expenses: |
|
|
|
|
|
Personnel-related (including stock-based compensation expense of
$1.7 million and $1.1 million for three months ended March 31, 2026
and 2025, respectively) |
|
4,124 |
|
|
|
3,024 |
|
Other general and administrative expenses(1) |
|
1,988 |
|
|
|
2,627 |
|
Total general and administrative expenses |
|
6,112 |
|
|
|
5,651 |
|
Other segment items(2) |
|
(2,135 |
) |
|
|
(3,060 |
) |
Net loss |
$ |
25,408 |
|
|
$ |
13,125 |
|
(1)Other general and administrative expenses include professional fees, facilities, depreciation, IT, and other expenses. (2)Other segment items include interest income, net, research and development tax credit, income tax provision, and other expense, net.
|